🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks to Yvonne Mowery from UPMC Hillman Cancer Center for an amazing translational talk! You’re really moving the needle in RadOnc (to be presented at ASCO24!) and I can’t wait to see what the future holds for you!

Congrats to Eyler Lab tech Alli Pittman, who was recently accepted into the Medical Scientist Training Program at the VCU SOM! Alli plans for a MD/PhD in molecular/cancer biology and credits Drs. Yvonne Mowery and Eyler as influential in her decision 🔗 radonc.duke.edu/news/spotlight…

Congrats Niema Razavian, MD on an outstanding residency. We are proud of all you have already achieved and can't wait to see what you do in the years to come. Thx for arranging one final HN/heme rotation this quarter so I can continue to brag on you to pts for the next few weeks!

Thanks for highlighting our surgical trial looking at frozen section directed biopsy vs WLE for high grade vulvar dysplasia. Enrollment open and hoping to gain insight into #QOL metrics for our patients. CT ID: NCT05934851

A labor of love lead by Katie Lichter MD MPH - with true passion and a calling to this developing research space in our field. Duke Radiation Oncology is proud to have contributed!

So thankful to have trained at the best program in the country with lifelong friends. Next stop: Salt Lake City, UT with Intermountain Health IntermountainMedCtr

So proud of Mark Chen !!! Duke Radiation Oncology

Two of my absolute favorite people and rad oncs! So thrilled that Rachel Blitzblau and Junzo Chino are receiving such recognition as the leaders of our field. Congratulations!!

Saturday morning well spent listening to Dustin Boothe discuss the future of #radioligand therapy- inspiring and informative! Intermountain Health IntermountainMedCtr

Its here! After 2⃣ years under review, our manuscript on unilateral neck treatment (🔪 and/or ☢️) in pts with tonsil cancer is out now in ORL. In this group of T1-2N0-2b pts, there were 0⃣ contralateral neck failures after unilat tx 🔗: tinyurl.com/3jnc2anv #radonc #hncsm

Hurricane Helene Resources 🌀 As the full scope of the damage left by Hurricane Helene becomes clear, here's what you need to know about Red Cross services and how to get help. If you're experiencing a life-threatening emergency, please call 911. • How is the Red Cross

There is a massive effort underway to get help to the people of western North Carolina including state and federal relief but we know there will be additional needs. If you would like to donate to the NC Disaster Relief Fund, visit nc.gov/donate.

In the midst of #ASTRO, there are probably thousands of patients cancer care being stopped due to #HurricaneHelene - consider donating to those in Western NC. I took care of many patients from this area as a resident Duke Radiation Oncology Durham VA Health Care System - I am devastated. ASTRO ARRO

#ASTRO24 - If you’re interesting in #radonc safety and QA ➡️ Check out the presentation by Ryan Hughes on virtual chart rounds! ☢️💻✅ Manuscript forthcoming!

🎙EUROPA Trial: ☢️ shows ⬆️ HRQOL and ⬇️⬇️ side effects vs. endocrine therapy in women 70+ with early-stage breast cancer❗️ OncoAlert 🎯 Objective: •☢️✖️ET as single-modality treatments for women aged ≥70 w/ luminal A-like breast cancer 🧪 Methods: •Design: Non-inferiority,

🚨Does #rads collaboration in #radonc peer review (PR) of contoured targets🎯impact treatment plans? New study in JAMA Network Open 🚨 PR is a critical component of RO, particularly important is the review of contoured🎯 doi.org/10.1001/jamane…

I'm excited to share our paper "Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma." Patients with DLBCL or PMBL achieving CR by PET, received dose-reduced ~20Gy consolidation RT--with no late local recurrences authors.elsevier.com/a/1kl6q1Hx52Ni…

I owe so much of my career and development to Mike Chan- such amazing news for Department of Radiation Oncology @ Wake Forest so well deserved 🎉

The #radonc oral boards results are in: 7️⃣7️⃣% of first time test takers passed - the lowest ⬇️ it’s been in since 2016 Wonder what was different this year 🤔

This study reports on incredible results with adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma. nejm.org/doi/full/10.10…